Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific acquires two chronic total occlusion treatments

Boston Scientific acquires two chronic total occlusion treatments

17th February 2011

Boston Scientific has announced the acquisition of two new medical technology offerings designed for the treatment of peripheral chronic total occlusions (CTOs).

In November 2010, the firm purchased a new re-entry catheter from Israel-based SI Therapies, while it will also take ownership of an intraluminal CTO crossing device via its acquisition of ReVascular Therapeutics, which will close this month.

The two devices are to be launched worldwide later this year and will allow endovascular treatments to be conducted in cases where guidewires and other catheter-based technologies cannot be applied.

Boston Scientific states that the acquisitions will broaden its portfolio and help clinicians to treat complex peripheral lesions, thus sparing patients from unnecessary surgery or lower extremity amputation.

Joe Fitzgerald, senior vice-president and president of Boston Scientific's endovascular unit, said: "The purchase of these innovative CTO technologies demonstrates a continued commitment to expanding our peripheral interventions business."

Earlier this month, the firm launched its new Renegade Hi-Flo Fathom Pre-Loaded System, a device with applications in a variety of vascular and interventional radiology areas.ADNFCR-8000103-ID-800411469-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.